Daniel Molnar

7PUBLICATIONS
39CO-AUTHORS
Epidemiological modellingMajor global burdens of diseaseDisease surveillancePacific Peoples epidemiologyPreventative health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 22, 2026
Comparison of Hospitalization Costs Associated With Human Metapneumovirus and Respiratory Syncytial Virus Infection in US Adults.

|Nov 26, 2025
Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.

Emily Rayens, Lina S Sy, Lei Qian

|Dec 09, 2024
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States.

Elizabeth M La, Jonathan Graham, David Singer

|Oct 22, 2024
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan.

Akiko Mizukami, Victor Preckler, Frederik Verelst

|Mar 20, 2024
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States.

Daniel Molnar, Elizabeth M La, Frederik Verelst

|Mar 01, 2024
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.

Daisuke Kurai, Akiko Mizukami, Victor Preckler

Pageof 2

Frequent Collaborators

3 joint publications

Frederik Verelst

2 joint publications

Taizo Matsuki

2 joint publications

Emily Rayens

2 joint publications

Jonathan Graham